These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36298493)

  • 1. Cost-Effectiveness Analysis of Cell Versus Egg-Based Seasonal Influenza Vaccination in Children and Adults in Argentina.
    Urueña A; Micone P; Magneres MC; McGovern I; Mould-Quevedo J; Sarmento TTR; Giglio N
    Vaccines (Basel); 2022 Sep; 10(10):. PubMed ID: 36298493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of the cell-based quadrivalent versus the standard egg-based quadrivalent influenza vaccine in Germany.
    Cai R; Gerlier L; Eichner M; Schwehm M; Rajaram S; Mould-Quevedo J; Lamotte M
    J Med Econ; 2021; 24(1):490-501. PubMed ID: 33761803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A real-world study evaluating the relative vaccine effectiveness of a cell-based quadrivalent influenza vaccine compared to egg-based quadrivalent influenza vaccine in the US during the 2017-18 influenza season.
    Divino V; Krishnarajah G; Pelton SI; Mould-Quevedo J; Anupindi VR; DeKoven M; Postma MJ
    Vaccine; 2020 Sep; 38(40):6334-6343. PubMed ID: 32739119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimated cost-effectiveness and burden of disease associated with quadrivalent cell-based and egg-based influenza vaccines in Spain.
    Ruiz-Aragón J; Gani R; Márquez S; Alvarez P
    Hum Vaccin Immunother; 2020 Sep; 16(9):2238-2244. PubMed ID: 32040379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Epidemiological and Economic Impact of a Cell-Based Quadrivalent Influenza Vaccine in Adults in the US: A Dynamic Modeling Approach.
    Nguyen VH; Hilsky Y; Mould-Quevedo J
    Vaccines (Basel); 2021 Sep; 9(10):. PubMed ID: 34696203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling the Economic Impact of lnfluenza Vaccine Programs with the Cell-Based Quadrivalent Influenza Vaccine and Adjuvanted Trivalent Influenza Vaccine in Canada.
    Nguyen VH; Roy B
    Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and Economic Outcomes Associated with Cell-Based Quadrivalent Influenza Vaccine vs. Standard-Dose Egg-Based Quadrivalent Influenza Vaccines during the 2018-19 Influenza Season in the United States.
    Krishnarajah G; Divino V; Postma MJ; Pelton SI; Anupindi VR; DeKoven M; Mould-Quevedo J
    Vaccines (Basel); 2021 Jan; 9(2):. PubMed ID: 33498724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Economic Evaluation of the Adjuvanted Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in the Spanish Older Adult Population.
    Fochesato A; Sottile S; Pugliese A; Márquez-Peláez S; Toro-Diaz H; Gani R; Alvarez P; Ruiz-Aragón J
    Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse events of interest following influenza vaccination, a comparison of cell culture-based with egg-based alternatives: English sentinel network annual report paper 2019/20.
    de Lusignan S; Tsang RSM; Amirthalingam G; Akinyemi O; Sherlock J; Tripathy M; Deeks A; Ferreira F; Howsam G; Hobbs FDR; Joy M
    Lancet Reg Health Eur; 2021 Mar; 2():100029. PubMed ID: 34557791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina.
    Urueña A; Micone P; Magneres C; Mould-Quevedo J; Giglio N
    Vaccines (Basel); 2021 Apr; 9(4):. PubMed ID: 33916048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-utility analysis of increasing uptake of universal seasonal quadrivalent influenza vaccine (QIV) in children aged 6 months and older in Germany.
    Molnar D; Anastassopoulou A; Poulsen Nautrup B; Schmidt-Ott R; Eichner M; Schwehm M; Dos Santos G; Ultsch B; Bekkat-Berkani R; von Krempelhuber A; Van Vlaenderen I; Van Bellinghen LA
    Hum Vaccin Immunother; 2022 Nov; 18(5):2058304. PubMed ID: 35486410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Cost-Effectiveness of Expanding Vaccination with a Cell-Based Influenza Vaccine to Low Risk Adults Aged 50 to 64 Years in the United Kingdom.
    Kohli MA; Maschio M; Mould-Quevedo JF; Ashraf M; Drummond MF; Weinstein MC
    Vaccines (Basel); 2021 Jun; 9(6):. PubMed ID: 34199912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Economic Comparison of Influenza Vaccines Recommended for Use in Eligible Adults under 65 Years in the United Kingdom.
    Maschio M; Kohli MA; Ashraf M; Drummond MF; Weinstein MC; Mould-Quevedo JF
    Vaccines (Basel); 2022 Apr; 10(4):. PubMed ID: 35455348
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost-effectiveness of introducing an MF59-adjuvanted trivalent influenza vaccine for older adults in Argentina.
    Nguyen VH; Vizzotti C; Uruena A; Giglio N; Magneres C; Richmond H
    Vaccine; 2020 Apr; 38(20):3682-3689. PubMed ID: 32249017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax
    Lamb YN
    Drugs; 2019 Aug; 79(12):1337-1348. PubMed ID: 31372959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany.
    Scholz SM; Weidemann F; Damm O; Ultsch B; Greiner W; Wichmann O
    Value Health; 2021 Jan; 24(1):32-40. PubMed ID: 33431151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany.
    Kohli MA; Maschio M; Cartier S; Mould-Quevedo J; Fricke FU
    Vaccines (Basel); 2022 Aug; 10(9):. PubMed ID: 36146464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model.
    Crépey P; Boiron L; Araujo RR; Lopez JG; Petitjean A; de Albuquerque Luna EJ
    BMC Public Health; 2020 Sep; 20(1):1374. PubMed ID: 32907562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea.
    Kim YK; Song JY; Jang H; Kim TH; Koo H; Varghese L; Han E
    Pharmacoeconomics; 2018 Dec; 36(12):1475-1490. PubMed ID: 30251078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the U.K.
    Meier G; Gregg M; Poulsen Nautrup B
    J Med Econ; 2015; 18(9):746-61. PubMed ID: 25903831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.